<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462902</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis with sepsis-01</org_study_id>
    <nct_id>NCT02462902</nct_id>
  </id_info>
  <brief_title>Comparison And Outcomes Of Fluid Resucitation With 0.9% Normal Saline And 5% Albumin In Cirrhosis Patients With Sepsis Induced Hypotension</brief_title>
  <official_title>Comparison And Outcomes Of Fluid Resucitation With 0.9% Normal Saline And 5% Albumin In Cirrhosis Patients With Sepsis Induced Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      300 consecutive patients with cirrhosis of any aetiology admitted with features of sepsis and&#xD;
      sepsis induced hypotension to the intensive care unit, the emergency department and the step&#xD;
      down units of Institute of Liver and Biliary Sciences, New Delhi, who fulfil the inclusion&#xD;
      criteria.&#xD;
&#xD;
      This study will be a single centre prospective randomized comparative trial. Patients will be&#xD;
      randomized into two groups. Group A will receive crystalloid, 0.9% sodium chloride solution&#xD;
      (total of 30ml/kg over 30 minutes) and Group B will receive colloid, 5% albumin (250 ml over&#xD;
      15 minutes).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of patients with MAP (Mean Arterial Pressure) â‰¥ 65</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lactate dynamics</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of patients with Urine output &gt;/= 0.5mL/kg/hr.</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Cirrhosis With Septic Shock</condition>
  <arm_group>
    <arm_group_label>5% albumin Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(250 ml over 15 to 30 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% sodium chloride solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minute)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% albumin Infusion</intervention_name>
    <description>colloid, 5% albumin (250 ml over 15 to 30 minutes).</description>
    <arm_group_label>5% albumin Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride solution</intervention_name>
    <description>0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)</description>
    <arm_group_label>0.9% sodium chloride solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cirrhotic patients of any aetiology with Infection - suspected or documented and Mean&#xD;
             arterial pressure less than 65 mm of Hg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cirrhosis patients in septic shock who are already on vasopressors and/or inotropes&#xD;
&#xD;
          2. Cirrhosis patients in septic shock with structural heart disease&#xD;
&#xD;
          3. Cirrhosis patients in septic shock with chronic renal failure/dialysis&#xD;
             dependent/volume overloaded state&#xD;
&#xD;
          4. Cirrhosis patients in shock, caused by other reasons, other than septic shock&#xD;
&#xD;
          5. Cirrhosis patients in septic shock in whom contraindication to internal jugular or&#xD;
             subclavian line insertion is present&#xD;
&#xD;
          6. Age less than 18 years&#xD;
&#xD;
          7. Previous episode of septic shock during the same hospital stay&#xD;
&#xD;
          8. Pregnant or lactating women&#xD;
&#xD;
          9. Patients in need for emergent surgical interventions&#xD;
&#xD;
         10. Cirrhosis patients in septic shock with chronic obstructive lung disease and right&#xD;
             heart failure&#xD;
&#xD;
         11. Cirrhosis patients in septic shock with associated upper gastrointestinal bleed or&#xD;
             coagulopathy related bleed with a haemoglobin of less than 8g/dL or requiring urgent&#xD;
             transfusions of blood and blood products&#xD;
&#xD;
         12. A previous adverse reaction to human albumin solution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>May 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

